Page 83 - Fisica In Medicina n° 1/2017

^Äëíê~Åí=jÉÇáÅá= =The role of Stereotactic body Radiotherapy (SBRT) in Oligorecurrent and in Oligoprogressive prostate cancer (PC): a multi-institutional studyL. TRIGGIANI1, P. GHIRARDELLI1, A. BRUNI2, F. ALONGI3, A. MAGLI4, A. BONETTA5, B. DETTI6, G.INGROSSO7, F.TRIPPA8, P. BORGHETTI1, R. D’ANGELILLO9, R. SANTONI7, L. LIVI6, M. BUGLIONE11Istituto del Radio, Spedali Civili, Università di Brescia 2U.O. Radioterapia Oncologica, AOU Policlinico di Modena, Modena 3S.C. Radioterapia Oncologica, Ospedale Sacro Cuore Don Calabria, Negrar (Vr) 4S.O.C. di Radioterapia Oncologica, Ospedale Santa Maria della Misericordia, Udine5U.O. Radioterapia, Ospedale di Cremona, Cremona 6SODc Radioterapia Oncologica, DAI Oncologia, A.O.U Careggi, Università di Firenze7U.O.C. di Radioterapia, Policlinico Tor Vergata, Università di Roma2 8U.O. Radioterapia, Ospedale Santa Maria Terni, Terni 9Campus Biomedico, RomaIntroductionSBRT is a safe and effective treatment which could postpone androgen deprivation therapy (ADT) in oligorecurrent PC. Despite that, in literature there is a lack of data about the role of SBRT in patients (pts) with oligoprogressive castrate resistant PC (oligo-CRPC). Our aim is to assess the feasibility and efficacy of SBRT in the treatment of oligorecurrent PC in terms of biochemical progression-free survival (BPFS) and ADT-free survival (ADT-FS) and also in pts with oligo-74